Illumina, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| ILMN | TLT | |
|---|---|---|
Market Cap | $39.95B | $47.61B |
Volume | 3,169,503 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $293.69 | $92.06 |
52-Week Low | $91.00 | $77.11 |
Typical Hold Time | 83 Days | 83 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.98, down 46% over five years amid a historic bond market selloff. The technical outlook is bearish with moving averages signaling continued pressure, while oscillators show neutral conditions. Recent news highlights Treasury yields reaching multi-decade highs above 5.3%, creating headwinds for long-duration bond funds despite recent dividend distributions.
The ETF faces significant interest rate risk as the Federal Reserve maintains higher rates, though current yields offer attractive income potential. Key risks include further rate hikes and inflation persistence, while potential catalysts include economic slowdowns that could drive bond prices higher. Institutional flows show mixed sentiment with recent large inflows despite price declines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →